AVTR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AVTR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.
Avantor's Capital Expenditure for the three months ended in Mar. 2025 was $-28.00 Mil. Its Operating Income for the three months ended in Mar. 2025 was $147.40 Mil.
Hence, Avantor's Capex-to-Operating-Income for the three months ended in Mar. 2025 was 0.19.
The historical data trend for Avantor's Capex-to-Operating-Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avantor Annual Data | |||||||||||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | ||||||||||
Capex-to-Operating-Income | Get a 7-Day Free Trial |
![]() |
0.09 | 0.11 | 0.12 | 0.17 | 0.23 |
Avantor Quarterly Data | ||||||||||||||||||||
Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | Mar25 | |
Capex-to-Operating-Income | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
0.24 | 0.26 | 0.33 | 0.14 | 0.19 |
For the Medical Instruments & Supplies subindustry, Avantor's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Avantor's Capex-to-Operating-Income distribution charts can be found below:
* The bar in red indicates where Avantor's Capex-to-Operating-Income falls into.
Avantor's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2024 is calculated as
Capex-to-Operating-Income | = | - Capital Expenditure | / | Operating Income |
= | - (-148.8) | / | 638.2 | |
= | 0.23 |
Avantor's Capex-to-Operating-Income for the quarter that ended in Mar. 2025 is calculated as
Capex-to-Operating-Income | = | - Capital Expenditure | / | Operating Income |
= | - (-28) | / | 147.4 | |
= | 0.19 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avantor (NYSE:AVTR) Capex-to-Operating-Income Explanation
Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.
Thank you for viewing the detailed overview of Avantor's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.
James Bramwell | officer: EVP, Strategic Partners | C/O AVANTOR, INC., 100 MATSONFORD ROAD, RADNOR PA 19087 |
Steven W Eck | officer: SVP & Chief Accounting Officer | C/O CSS INDUSTRIES, INC., 450 PLYMOUTH ROAD, SUITE 300, PLYMOUTH MEETING PA 19462 |
Christophe Couturier | officer: See Remarks | 9 FOURTH AVENUE, C/O OVASCIENCE INC., CAMBRIDGE MA 02451 |
Benoit Gourdier | officer: EVP, Biopharma Production | 100 MATSONFORD ROAD, RADNOR PA 19087 |
Frederic Vanderhaegen | officer: EVP, Europe | C/O AVANTOR, INC., 100 MATSONFORD ROAD, RADNOR PA 19087 |
Brittany Hankamer | officer: EVP, Chief HR Officer | 100 MATSONFORD ROAD, RADNOR PA 19087 |
R. Brent Jones | officer: EVP, Chief Financial Officer | C/O PALL CORPORATION, 25 HARBOR PARK DRIVE, PORT WASHINGTON NY 11050 |
Claudius Sokenu | officer: EVP, Chief Legal & Compliance | C/O UNISYS CORPORATION, 801 LAKEVIEW DRIVE, BLUE BELL PA 19422 |
Randy Lee Stone | officer: EVP, Proprietary Products | 974 CENTRE ROAD, CRP 730, WILMINGTON DE 19805 |
Gerard Brophy | officer: EVP, Biopharma Production | C/O AVANTOR, INC., 100 MATSONFORD ROAD, RADNOR PA 19087 |
Kitty Sahin | officer: EVP, Strategy&Corp Development | 100 MATSONFORD ROAD, RADNOR PA 19087 |
Michael Stubblefield | director, officer: President and CEO | C/O AVANTOR, INC., 100 MATSONFORD ROAD, RADNOR PA 19087 |
Thomas A Szlosek | officer: EVP and CFO | HONEYWELL INTERNATIONAL INC., 115 TABOR ROAD, MORRIS PLAINS NJ 07950 |
Rajiv Gupta | director | 234 RAVENCLIFF DRIVE, ST DAVIDS PA 19087 |
Joseph R Massaro | director | 5725 DELPHI DRIVE, TROY MI 48098 |
From GuruFocus
By GuruFocus News • 03-22-2025
By GuruFocus News • 02-06-2025
By GuruFocus News • 02-07-2025
By GuruFocus News • 02-08-2025
By PRNewswire • 03-17-2025
By GuruFocus News • 04-14-2025
By GuruFocus News • 02-07-2025
By GuruFocus News • 04-16-2025
By GuruFocus News • 03-07-2025
By GuruFocus News • 02-08-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.